Issue 1 JANUARY 2019

The Veeda Newsletter

Clinicla Research

Researchers testing drug that reduces breast cancer by 50 percent

A new drug has been found to reduce the risk of cancer reoccurring by 50 percent and a Richmond hospital is behind a major medical breakthrough for breast cancer patients.

Orphan drug development and the urgent need for a new approach

There are around 7,000 rare or ‘orphan’ diseases for which there currently exists no authorized or satisfactory method of treatment. Many are life-threatening or debilitating, and they particularly affect the very young, who often do not survive beyond adolescence.
Read more at:

How the pharma industry may be impacted by drug pricing and other policies in 2019?

Two years later, when you ask pharma people for their overarching thoughts about their fate so far under President Donald Trump, their responses are peppered with disbelieving giggles
Read more :

CDMO Identifies Trends Affecting the Generic Drugs Sector in 2019

PCI Synthesis, Inc., a pharmaceutical manufacturer of new chemical entities (NCEs), generic active pharmaceutical ingredients (APIs), and other specialty chemical products, issued its annual list of trends that will affect the emerging biotech and generic drug sectors
Read more at:

5 Biopharma Trends to Watch in 2019

Biopharma industry watchers, executives, and especially investors often display that same desire as a year comes to a close, which explains why there’s typically a wave of news articles and commentaries attempting to divine events of the coming year based on the 12 months that are coming to a close.
Read more at:
Contact Us